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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
• To assess the benefits and harms of each cholinesterase inhibitor in the treatment of adults with VCI
• To compare cholinesterase inhibitors for efficacy and safety in people with VCI
B A C K G R O U N D
Description of the condition
Vascular cognitive impairment (VCI) is a clinical syndrome that
comprises a broad spectrum of cognitive impairments that occur
as a result of vascular disease (pathology), ranging from subjec-
tive cognitive decline and mild cognitive impairment to dementia
(Dichgans 2017; van de Flier 2018). The Vascular Impairment
of Cognition Classification Consensus Study (VICCCS) has pro-
duced a revised conceptualisation of VCI (Skrobot 2017), in which
VCI is divided into mild and major subtypes according to the
level of impairment. Mild VCI is not subdivided, but major VCI
(vascular dementia) has four subdivisions: post stroke dementia,
subcortical ischaemic vascular dementia, multi-infarct ( cortical)
dementia, and mixed dementias. For the purpose of this review,
we will treat VCI as the umbrella term that incorporates vascular
dementia and other cognitive syndromes with a presumed vascular
basis ( as listed in the VICCCS definition, including mild VCI
and all subdivisions of major VCI). Two criteria must be met for
a diagnosis of VCI: firstly, a demonstration of a cognitive deficit
through neuropsychological testing, and secondly, the presence of
cerebrovascular disease. VCI is further classified as ‘probable’ or
‘possible’, according to the presence of conclusive evidence demon-
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strating a causal relationship between the cognitive impairment
and the vascular disease ( Dichgans 2017).
The clinical presentation of VCI depends on the type, extent
and location of the underlying cerebrovascular pathology. Possible
symptoms of VCI are numerous and include memory problems,
mental slowness and problems with executive function (such as
planning, sequencing and problem solving). Patients report dif-
ficulties with higher-order cognitive functions, such as planning,
organising and monitoring behaviour. Behavioural symptoms and
psychological symptoms, including emotional lability, anxiety, de-
pression and apathy are also commonly reported. Other neuro-
logical signs and symptoms often occur, including reflex asymme-
try, dysarthria (difficulty with speech), gait disorders and prob-
lems with balance, parkinsonism, rigidity, or urinary incontinence
(O’Brien 2003; van de Flier 2018). VCI due to single infarcts
(damage to a part of the brain due to stroke) presents abruptly,
while symptoms and signs due to subcortical damage from the
resulting lacunae or from white matter disease (a progressive age-
related decline in nerves that connect areas of brain to each other)
typically develop more insidiously (Erkinjuntti 2004).
As life expectancy increases, VCI has become a growing public
health issue. According to recent estimates, approximately 36 mil-
lion people have dementia worldwide, and this number is expected
to reach 66 million by 2030 and 115 million by 2050 (Wortmann
2012). In affluent countries, the prevalence of dementia after 65
years is reported to be between 5% and 10% (Gorelick 2011).
Vascular dementia is the second most common form of dementia
after Alzheimer’s disease and accounts for at least 20% of dementia
cases (Wu 2016). The prevalence of VCI is strongly considered
to be age-related. In subjects aged between 65 and 84 years, the
prevalence of mild forms of VCI that do not reach the criteria
required for a diagnosis of dementia is higher than that of vascular
dementia. Rates of conversion to dementia, institutionalisation,
and mortality are significantly increased in these patients, suggest-
ing that patients with mild VCI are an important target popula-
tion for prevention of poor outcomes (Dichgans 2017).
Description of the intervention
Accurate assessment and management of vascular risk factors are
a key priority in the treatment of VCI, particularly early in the
disease when preventive strategies may prove to be more effective
(Ritter 2015). Although primary prevention trials have suggested
that treatment of hypertension, adherence to a Mediterranean diet,
physical activity, and smoking cessation may reduce the risk of
cognitive decline, there is limited evidence regarding these inter-
ventions for improving cognition in VCI (Ritter 2015). Currently,
there are no specific pharmacological treatments recommended
for improving either cognition or function in VCI. Management
strategies used for patients with VCI are similar to those for other
forms of dementia. Key principles include treating psychological
and behavioural comorbidities, providing information and sup-
port to the patient and caregivers, and maximising the patient’s
independence ( Dichgans 2017).
Cholinesterase inhibitors are medicines recommended as options
for managing mild to moderate dementia due to Alzheimer’s
disease in several clinical guidelines (Hort 2010; NICE 2018).
Alzheimer’s disease is the most common cause of dementia and
is found in approximately 70% of autopsies of people with de-
mentia (Qiu 2009). The three cholinesterase inhibitors currently
marketed for the treatment of Alzheimer’s disease are donepezil,
rivastigmine and galantamine. Cholinesterase inhibitors are taken
orally once or twice a day, or, in the case of rivastigmine, can be
applied transdermally.
Well-designed, placebo-controlled trials involving large num-
bers of participants have reported modest cognitive benefit from
cholinesterase inhibitors in mild to moderate dementia due to
Alzheimer’s disease (Hansen 2008). However, a number of harms
due to the use of cholinesterase inhibitor treatment have also been
reported. A previous Cochrane Review reported that there is ev-
idence of more adverse events overall in people treated with a
cholinesterase inhibitor than with placebo. Nausea, vomiting and
diarrhoea in particular are reported significantly more frequently
in the cholinesterase inhibitor groups than in the placebo groups
(Birks 2006).
How the intervention might work
Cholinesterase inhibitors inhibit the activity of the enzyme acetyl-
cholinesterase, and increase acetylcholine levels by decreasing the
rate at which the substance is broken down. The aim of prescribing
cholinesterase inhibitors for Alzheimer’s disease is to compensate
for the loss of cholinergic brain cells and to boost cholinergic neu-
rotransmission in forebrain regions (Colovi 2013). Reductions
in acetylcholine and acetyltransferase activity (markers of cholin-
ergic neurotransmission) are common to both Alzheimer’s disease
and VCI, raising the possibility that these drugs are beneficial for
the former may also be beneficial for the latter (Toghi 1996; Perry
1997). Rivastigmine is a ’pseudo-irreversible’ inhibitor of acetyl-
cholinesterase and also of butyryl-cholinesterase, which is a non-
specific cholinesterase enzyme. Galantamine is a reversible, com-
petitive inhibitor of acetylcholinesterase with minimal butyryl-
cholinesterase inhibitory activity (Lilienfeld 2002). Donepezil is a
second-generation cholinesterase inhibitor, which is a non-com-
petitive, reversible antagonist of cholinesterase and is highly se-
lective for acetylcholinesterase compared to butyryl-cholinesterase
(Dawbarn 2001).
Why it is important to do this review
To date, the US Food and Drug Administration and the European
Medicines Agency have not approved any pharmacological treat-
ments for VCI or Vascular dementia symptoms. As no established
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standard treatment for VCI exists, clinicians must extrapolate from
large primary and secondary prevention trials in ischaemic heart
disease, hypertension and stroke.
Three previous Cochrane Reviews have investigated the efficacy
and safety of separate cholinesterase inhibitors for VCI. The review
of donepezil for VCI reported some improvements in cognitive
function and activities of daily living as well as more global mea-
sures of change (Malouf 2004). The review investigating galan-
tamine in VCI concluded that there were some advantages over
placebo in the areas of cognition and global clinical state (Craig
2006). Similarly, rivastigmine had some benefit on cognitive re-
sponse at 24 weeks in people with VCI (Birks 2013). However,
these reviews provided no evidence of potential differences in ef-
ficacy between these medications, and a review that combines the
evidence would be helpful to clinicians.
A number of years have passed since the publication of the orig-
inal reviews. This new over-arching review will ensure that any
new trials are included. It will also allow the use of contemporary
approaches to evidence synthesis (e.g. use of GRADE methods
to assess evidence quality) that were not in use at the time the
previous reviews were written. For the first time, we will include
all cholinesterase inhibitors in a network meta-analysis (NMA) in
order to address the uncertainty about which cholinesterase in-
hibitor, if any, is most efficacious and safe in the management of
VCI (Salanti 2012).
O B J E C T I V E S
• To assess the benefits and harms of each cholinesterase
inhibitor in the treatment of adults with VCI
• To compare cholinesterase inhibitors for efficacy and safety
in people with VCI
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all parallel-group, randomised trials in which par-
ticipants with VCI are assigned to treatment with a cholinesterase
inhibitor or placebo, or to alternative cholinesterase inhibitors. We
will include any identified trial regardless of publication status.
We will discuss randomised, controlled trials of a cholinesterase
inhibitor for VCI which do not meet the inclusion criteria briefly
in the ’Excluded studies’ section.
Types of participants
We will include patients diagnosed as having VCI on the basis
of any validated and internationally recognised diagnostic frame-
work for dementia, including the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM) (APA 2013), and the Interna-
tional Classification of Diseases of the World Health Organiza-
tion (ICD) (WHO 1992), and any classification systems specific
to VCI, such as the National Institute of Neurological Disorders
and Stroke and the Association International pour la Recherche
et l’ Enseignement en Neurosciences (NINDS/AIREN) (Roman
1993). Diagnosis of VCI with no dementia will be based on scores
on cognitive impairment scales with a clinical diagnosis to ensure
distinction between vascular and non-vascular impairment.
From previous reviews we anticipate that studies of cholinesterase
will be limited to a population with defined dementia pathology,
for example VCI, Alzheimer’s disease. Where the population is
composed of a mixed group, we will include if the proportion
with VCI is greater than 80%. For studies of undifferentiated
dementia or where dementia subtype is not described, we will
exclude, as based on general population frequencies, it would be
unlikely that the pool of participants would have more than 80%
VCI pathology.
Types of interventions
For our new over-arching review investigating the efficacy of indi-
vidual cholinesterase inhibitors, our primary analysis will focus on
trials of cholinesterase inhibitor monotherapy (i.e. rivastigmine,
galantamine or donepezil) versus placebo control.
These medications can be administered orally or, in the case of ri-
vastigmine, transdermally. In our primary analysis we will include
both routes in a single summary analysis. Reviews in non-vascu-
lar dementia suggest that oral and transdermal preparations have
different profiles for adverse effect, so we will perform a subgroup
analysis to compare the efficacy and tolerability of the two routes
in this population.
The licensed cholinesterase inhibitors are available in a range of
doses. The drugs usually have a dose-titration period. In our anal-
yses, we will consider the final dose achieved. Reviews in non-vas-
cular dementias suggest doses may differ in efficacy and adverse
events. For donepezil, we will include studies where the final dose
is a licensed oral dose of 5 mg, 10 mg or 23 mg daily; we will
consider each dose separately. For rivastigmine, we will assess the
manufacturer’s recommended final dose of 6 mg to 12 mg daily
for the oral preparation, or 4.6 mg/24 hours or 9.5 mg/24 hours
for the transdermal preparation; other doses, if studied, will be
considered separately. For galantamine, we will assess the manu-
facturer’s recommended oral dose of 16 mg to 24 mg; other doses,
if studied, will be considered separately. For galantamine, we will
consider standard and modified-release preparations in the same
analysis.
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Trials that compare one cholinesterase inhibitor with another will
be included in the NMA only.
Types of outcome measures
Primary outcomes
We will estimate the relative effects of the interventions where
reported at up to 3 months, from 3 months to 6 months, from 6 to
18 months, and more than 18 months, according to the following
primary outcomes :
• Clinical Global Impression (e.g. Clinician’s Interview-Based
Impression of Change scale, CIBIC-Plus; The Clinical Global
Impression of Change, CGIC; Clinical Global Impression, CGI;
The Sandoz Clinical Assessment Geriatric Scale, SCAG);
• Cognitive function (e.g. the cognitive part of the
Alzheimer’s Disease Assessment Scale, ADAS-Cog; Syndrom-
Kurz test);
• Functional performance in activities of daily living (e.g.
Alzheimer’s Disease Cooperative Study-Activities of Daily
Living, ADCS-ADL; Behavioural Rating Scale for Geriatric
Patients, BGP);
• The number of adverse events. If the number of adverse
events is not presented, we will take the number of participants
with any adverse events (one or more) in a study. We will accept
adverse events as defined in the included studies.
Secondary outcomes
• Serious adverse events (SAEs), including death
• Incidence of development of new dementia: if any studies
are concerned exclusively with vascular mild cognitive
impairments or related syndromes, then we will describe rates of
incident dementia as an outcome. This outcome will be
considered separately to the other outcomes of interest to the
dementia population.
• Behavioural disturbance (e.g. Neuropsychiatric Inventory,
NPI)
• Carer burden
• Institutionalisation
• Quality of life
Search methods for identification of studies
Electronic searches
We will search ALOIS ( www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) specialized register.
ALOIS is maintained by the Information Specialists for the
Cochrane Dementia and Cognitive Improvement Group, and
contains studies that fall within the areas of dementia prevention,
dementia treatment and management, and cognitive enhancement
in healthy elderly populations. The studies are identified through:
1 Searching a number of major healthcare databases: MEDLINE,
Embase, CINAHL and PsycINFO;
2 Searching a number of trial registers: ClinicalTrials.gov and the
World Health Organization’s International Clinical Trials Register
Platform (ICTRP) which covers ISRCTN; the Chinese Clinical
Trials Register; the German Clinical Trials Register; the Iranian
Registry of Clinical Trials and the Netherlands National Trials
Register, plus others;
3 Searching the Cochrane Library’s Central Register of Controlled
Trials (CENTRAL);
4 Searching grey literature sources: ISI Web of Science Core Col-
lection;
To view a list of all sources searched for ALOIS on the ALOIS web
site ( www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed
on the Cochrane Dementia and Cognitive Improvement Group’s
website: http://dementia.cochrane.org/searches
We will run additional searches in MEDLINE, Embase,
PsycINFO, Cinhal, LILACs, ClinicalTrials.gov and the WHO
Portal/ICTRP, from incpetion, to ensure that the searches for this
review are as comprehensive and as up-to-date as possible. The
search strategy that will be used for the retrieval of reports of tri-
als from MEDLINE (via the Ovid SP platform) can be seen in
Appendix 1.
Searching other resources
We will check the reference lists of eligible studies and previous
systematic reviews to identify additional studies. We will contact
the corresponding authors of the most recent systematic reviews
on cholinesterase inhibitors in vascular cognitive impairment to
enquire whether they are aware of any additional studies in the
area of their review. We will search clinical trial registries (World
Health Organization (WHO) International Clinical Trial Registry
Platform (ICTRP) search portal; EU clinical trial register; Clin-
icalTrials.gov) for the protocols and registrations of all included
studies. We will contact the pharmaceutical companies (Eisai and
Pfizer for donepezil (Aricept); Shire for galantamine (Reminyl);
Lunbeck for rivastigmine (Exelon)), and search their press releases
pertaining to ChIEs. We will also request all conference posters
presented by relevant authors and those sponsored by the phar-
maceutical companies. We will seek other grey literature through
handsearching of reference lists of the relevant trials and systematic
reviews we retrieve. We will also handsearch relevant conference
abstracts that are not covered in ALOIS, specifically; International
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Stroke Conference 2017-2019 (published in Stroke). European
Stroke Organisation Conference 2017-2019 (Published in Euro-
pean Stroke Journal) and Alzheimer’s Association International
Conference 2017-2019 (Published in Alzheimer’s and Dementia
journal).
Data collection and analysis
Selection of studies
Independently, two review authors (CB and AHAR) will assess all
the potential studies we identify as a result of the search strategy for
inclusion. We will resolve any disagreements through discussion
or, if required, we will consult a third review author (TJQ). We
will create a PRISMA study flow diagram to map out the number
of records identified, included and excluded. We will list all studies
excluded after full-text assessment and their reasons for exclusion
in a ’Characteristics of excluded studies’ table.
Data extraction and management
We will extract data on results from the primary outcome measures
at the following time points, where reported: up to 3 months, from
3 months to 6 months, from 6 to 18 months, and more than 18
months. We will extract data from more than one time point, if
available.
Data on potential effect modifiers
From each included study we will extract the following data that
may act as effect modifiers:
• population: diagnostic criteria; baseline mean age; male-to-
female ratio; co-morbidities; concurrent medications, ethnicity
and socioeconomic status;
• interventions: duration of the intervention, including
duration of any washout, run-in or titration period; dosage
regimen, including during any titration period; route of
administration;
• outcome measures: measure used, time point completed;
• ’risk of bias’ domains (see Assessment of risk of bias in
included studies);
• funding sources.
Assessment of risk of bias in included studies
The risk of bias in each study will be assessed independently by two
review authors (CEB and AHAR), and any disagreement will be re-
solved by discussion to reach consensus, involving a third reviewer
(TJQ), if necessary. We will assess the risk of bias of each included
study using the Cochrane criteria (Higgins 2017), which include
assessment of the following domains: random sequence genera-
tion, allocation concealment, blinding of participants, blinding
of outcome assessment, incomplete outcome data, and selective
outcome reporting. We will judge the level of risk of bias within
each study explicitly for each domain as being at ’low’, ’high’, or
’unclear’ risk of bias. We will describe all judgements fully and
present the conclusions in the ’risk of bias’ tables.
We will judge studies as being at low risk of bias in the incomplete
outcome data domain when numbers and causes of dropouts are
balanced between arms. For continuous outcomes, we will con-
sider the following factors: the level of missing data, the difference
between groups, and the reasons for missingness. We will also take
into account whether the approach to missing data (e.g. observed
case (OC) or last observation carried forward (LOCF)) gave dif-
ferent effect estimates. For dichotomous outcomes, we will com-
pare the proportions missing in each group with each other and
with the adverse event risk. If there is a substantial difference in
missing data between groups, or the proportion of missing data
is comparable with the adverse events risk, we will rate the risk of
attrition bias as high. We will assess selective outcome reporting
by comparing outcomes the trialists intended to analyse against
the published study results. Where no trial protocol is available,
we will assign a judgement of high risk of bias when study results
do not include the primary outcome measures of the review.
Measures of treatment effect
For binary outcomes, we will use odds ratios (ORs) with 95%
confidence intervals (CIs) as the measure of treatment effect. For
continuous outcomes, we will use mean differences (MDs) with
95% CI. If different instruments are used to measure the same
continuous outcome, we will use the standardised mean difference
(SMD) with 95% CIs. If participant-related outcomes are reported
both as binary and continuous outcomes, we will analyse binary
outcomes in one analysis and continuous outcomes in another
analysis. For time-to-event outcomes, we will use hazard ratios
(HRs) and their 95% CIs.
We will present results from network meta-analysis (NMA) as
summary relative effect sizes for each possible pair of treatments.
Relative treatment ranking
For each study intervention, we will also estimate the ranking
probabilities for all treatments of being at each possible rank. We
will then obtain a treatment hierarchy using the surface under
the cumulative ranking curve (SUCRA) and mean ranks (Salanti
2011).
Unit of analysis issues
We do not anticipate any cluster randomised or cross-over trials.
If any such trials are retrieved, we will follow guidance from the
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Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2017).
For multi-arm trials, we will include all intervention groups that
would meet the criteria for inclusion in pairwise comparisons, if
they were investigated alone.
Dealing with missing data
In order to assess the effect of missing outcome data, we plan to
use OC analyses wherever possible, but in some analyses, we may
have to pool trials reporting OC and LOCF data. This will be
made explicit in the accompanying text. We will assess the impact
of this OC approach in a sensitivity analysis, by comparing the
results of analyses based on the two main approaches (OC and
LOCF). We will report the degree of missing data explicitly in the
Characteristics of included studies section. Where mixed methods
or area-under-the curve methods are reported by study authors,
we will extract the results from these analyses only if OC results
are unavailable.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
within treatment comparisons
To evaluate the presence of heterogeneity deriving from different
trial designs or different clinical characteristics of study partici-
pants, we will generate descriptive statistics for trial and study pop-
ulation characteristics across all eligible trials that compare each
pair of interventions. Two authors will assess the presence of clin-
ical heterogeneity within each pairwise comparison by comparing
these characteristics. Statistical heterogeneity will be assessed using
the I2 statistic and its 95% CI that measures variability that cannot
be attributed to random error. We will take an I2 measurement of
more than 50% as indicative of substantial heterogeneity (Higgins
2017).
Assessment of transitivity across treatment comparisons
We expect that the transitivity assumption will hold, with the as-
sumption that all pairwise comparisons will not differ with respect
to the distribution of effect modifiers (for example, rivastigmine,
galantamine and donepezil will have been administered in a sim-
ilar way across all included trials).
We will evaluate the assumption of transitivity by comparing the
clinical and methodological characteristics (potential effect mod-
ifiers presented in Data extraction and management) across the
different pairwise comparisons.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we will aim to minimise the po-
tential impact of these biases by ensuring a comprehensive search
for eligible studies and by being alert to duplication of data. If
there are 10 or more studies in the NMA, we will use a funnel
plot to explore the possibility of small study effects (a tendency
for estimates of the intervention effect to be more beneficial in
smaller studies) and account for the fact that studies estimate ef-
fects for different comparisons. The funnel plots will be aggregate
combining all relevant studies.
Data synthesis
Methods for direct treatment comparisons
We will perform standard pairwise meta-analyses using a fixed-
effect model in the review-writing software Review Manager 5.3
for every treatment comparison at our prespecified time points,
where the summary analysis will include at least two studies (
Review Manager 2014). If substantial heterogeneity is found (i.e.
an I2 value > 50%), we will analyse the data using a random-effects
model.
Methods for indirect and mixed comparisons
NMA is a method used to synthesise information from a network
of trials that address the same question, but involve different in-
terventions. NMA combines direct and indirect evidence across a
network of randomised trials into a single effect size, and, under
certain assumptions, it can increase the precision of the estimates
while respecting randomisation. The models will enable us to es-
timate the probability that each intervention is the best for each
outcome, given the relative effect sizes as estimated in NMA.
Each cholinesterase inhibitor and dose will be considered as a sep-
arate intervention (node) in the analysis. The NMA will compare
the cholinesterase inhibitor medications and doses to one another.
We will report the findings for these interventions in the results
and the conclusions of the review.
We assume that the three cholinesterase inhibitors (donepezil, ri-
vastigmine and galantamine), are directly comparable treatments.
In other words, we assume that the distribution of important char-
acteristics (effect modifiers) is the same across all treatment com-
parisons (Salanti 2012). The placebo node is defined as any drug
intervention that does not contain an active ingredient, or any trial
arm that contains no investigator-intended treatment.
We will perform NMA for each primary outcome measure, using
MetaInsight, (bespoke NMA software developed by the University
of Leicester). We will receive support in the design, analyses and
interpretation of the NMA from the National Institute for Health
Research (NIHR) Complex Reviews Support Unit.
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Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
As we expect to have few studies (around two to four) in each direct
comparison, in standard pairwise meta-analysis we will assume
a common heterogeneity variance for all direct comparisons. In
NMA we will assume a common estimate for the heterogeneity
variance across the different comparisons.
Measures and tests for heterogeneity
The assessment of statistical heterogeneity in the entire network
will be based on the magnitude of the heterogeneity variance pa-
rameter (T2) estimated from the NMA models. For dichotomous
outcomes the magnitude of the heterogeneity variance will be com-
pared with the empirical distribution as derived by Turner (Turner
2012). We will also estimate a total I2 value for heterogeneity in
the network as described elsewhere (Jackson 2014).
Assessment of statistical inconsistency
Consistency in a network of interventions refers to the agreement
between direct and indirect evidence on the same comparisons.
If the network is substantially inconsistent, joint analysis can be
misleading. Differences in trial protocols, inclusion or exclusion
criteria, and effect modifiers within the network will lead to in-
consistency.
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally we will use the
loop-specific approach. This method evaluates the consistency as-
sumption in each closed loop of the network separately as the dif-
ference between direct and indirect estimates for a specific com-
parison in the loop (inconsistency factor) (Veroniki 2013). The
magnitude of the inconsistency factors and their 95% CIs can
then be used to infer information about the presence of incon-
sistency in each loop. We will assume a common heterogeneity
estimate within each loop. We will present the results of this ap-
proach graphically in a forest plot using MetaInsight (University
of Leicester).
Global approaches for evaluating inconsistency
To check the assumption of consistency in the entire network we
will use the ‘design-by-treatment’ model as described by Higgins
2017. This method accounts for different sources of inconsistency
that can occur when studies with different designs (two-arm trials
versus three-arm trials) give different results as well as disagree-
ments between direct and indirect evidence. Using this approach,
we will draw inferences about the presence of inconsistency from
any source in the entire network based on a Chi2 test. Inconsis-
tency and heterogeneity are interwoven; to distinguish between
these two sources of variability we will employ the I2 for inconsis-
tency, as it measures variability that cannot be attributed to ran-
dom error or heterogeneity (within comparison variability). We
will also seek guidance from the NIHR Complex Reviews Support
Unit, to address any inconsistencies.
Investigation of heterogeneity and inconsistency
If sufficient studies are available, we will perform network meta-
regression or subgroup analyses, or both, by using the following
effect modifiers as possible sources of inconsistency or heterogene-
ity, or both: baseline severity, diagnostic criteria, duration of in-
tervention.
Sensitivity analysis
If sufficient studies are identified for each comparison, we will
undertake sensitivity analyses that include only trials that we have
rated as being at low risk of bias across all domains.
We will conduct sensitivity analyses including only participants
with vascular dementia, that is, excluding trials in which some or
all participants have mild VCI.
’Summary of findings’ table
The main results of the review will be presented in ‘Summary of
findings’ (SoF) tables as recommended by Cochrane (Schünemann
2011). We will include overall grading of the evidence for the
primary outcomes and SAEs for each comparison, based on the
methodology developed by the GRADE Working Group (Puhan
2014). We will assess the quality of evidence using the GRADE
criteria: study limitations, indirectness, inconsistency, imprecision
of events estimates, and risk of publication bias. We will assign four
levels of evidence quality to our results; high, moderate, low and
very low, using GRADEpro GDT software (GRADEpro GDT).
We will provide estimates of the direct and indirect evidence and
of the network meta-analysis.
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Appendix 1. MEDLINE search strategy
1 exp CADASIL/
2 exp Cerebrovascular Disorders/
3 exp Dementia, Multi-Infarct/
4 exp Dementia, Vascular/
5 exp Neurocognitive Disorders/
6 “subcortical ischemic vascular disease*”.ti,ab.
7 “vascular cognitive impairment*”.ti,ab.
8 “vascular dement*”.ti,ab.
9 dement*.ti,ab.
10 VaD.ti,ab.
11 VCI.ti,ab.
12 or/1-11
13 exp Cholinesterase Inhibitors/
14 exp TACRINE/
15 exp GALANTAMINE/
16 exp Donepezil/
17 “acetylcholinesterase inhibitor*”.ti,ab.
18 “anti-alzheimer* ADJ2 drug*”.ti,ab.
19 “anti-cholinesteras*”.ti,ab.
20 “anti-dementia drug*”.ti,ab.
21 “cholinesterase inhibitor*”.ti,ab.
22 “memory drug”.ti,ab.
23 “SDZ ENA 713”.ti,ab.
24 Anticholinesterase*.ti,ab.
25 anti-cholinesterase.ti,ab.
26 aricept.ti,ab.
27 cognex.ti,ab.
28 donezepil.ti,ab.
29 E2020.ti,ab.
30 exelon.ti,ab.
31 galantamine.ti,ab.
32 galanthamine.ti,ab.
33 Nivalin.ti,ab.
34 Razadyne.ti,ab.
35 reminyl.ti,ab.
36 rivastigmine.ti,ab.
37 tacrine.ti,ab.
38 or/13-37
39 12 and 38
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